遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践
收稿日期: 2024-01-08
网络出版日期: 2025-01-23
Hereditary breast cancer risk gene assessment and counseling: interpretation of NCCN guidelines and Ruijin Hospital clinical practice
Received date: 2024-01-08
Online published: 2025-01-23
韩梦圆 , 陈小松 . 遗传性乳腺癌风险基因检测与咨询：NCCN指南解读与瑞金医院临床实践[J]. 外科理论与实践, 2024 , 29(05) : 401 -404 . DOI: 10.16139/j.1007-9610.2024.05.06
Hereditary breast cancer-related gene mutations significantly increase the risk of breast cancer in women. In this regard, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment was developed to guide genetic assessment and counseling in mutation carriers of breast cancer risk genes, providing crucial information for the prevention, screening and treatment of breast cancer. This article provided an interpretation of the NCCN Clinical Practice Guidelines in Genetic/Familial High-Risk Assessment, integrating the clinical practice experience of Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.
Key words： Breast cancer; Hereditary risk gene; Gene mutation; NCCN guidelines; Practice
| [1] | Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours[J]. Nature, 2012, 490(7418):61-70. |
| [2] | DALY M B, PAL T, MAXWELL K N, et al. NCCN Guidelines? Insights: Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2024[J]. J Natl Compr Canc Netw, 2023, 21(10):1000-1010. |
| [3] | LANCASTER J M, POWELL C B, CHEN L M, et al. Society of gynecologic oncology statement on risk assessment for inherited gynecologic cancer predispositions[J]. Gynecol Oncol, 2015, 136(1):3-7. |
| [4] | COHEN SA, BRADBURY A, HENDERSON V, et al. Genetic counseling and testing in a community setting: qua-lity, access, and efficiency[J]. Am Soc Clin Oncol Educ Book,2019,39:e34-e44. |
| [5] | FORREST L E, YOUNG M A. Clinically significant germline mutations in cancer-causing genes identified through research studies should be offered to research participants by genetic counselors[J]. J Clin Oncol, 2016, 34(9):898-901. |
| [6] | ROBSON M, IM S A, SENKUS E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6):523-533. |
| [7] | LITTON J K, RUGO H S, ETTL J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8):753-763. |
| [8] | TUTT A N J, GARBER J E, KAUFMAN B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer[J]. N Engl J Med, 2021, 384(25):2394-2405. |
| [9] | Breast Cancer Association Consortium; MAVADDAT N, DORLING L, CARVALHO S, et al. Pathology of tumors associated with pathogenic germline variants in 9 breast cancer susceptibility genes[J]. JAMA Oncol, 2022, 8(3):e216744. |
| [10] | XICOLA R M, LI S, RODRIGUEZ N, et al. Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria[J]. J Med Genet, 2019, 56(12):838-843. |
| [11] | HENDRICKS L A J, HOOGERBRUGGE N, VENSELAAR H, et al. Genotype-phenotype associations in a large PTEN Hamartoma Tumor Syndrome (PHTS) patient cohort[J]. Eur J Med Genet, 2022, 65(12):104632. |
| [12] | Breast Cancer Association Consortium; DORLING L, CARVALHO S, ALLEN J, et al. Breast cancer risk genes - association analysis in more than 113,000 women[J]. N Engl J Med, 2021, 384(5):428-439. |
| [13] | UUSITALO E, RANTANEN M, KALLIONP?? R A, et al. Distinctive cancer associations in patients with neurofibromatosis type 1[J]. J Clin Oncol, 2016, 34(17):1978-1986. |
| [14] | VAN LIER M G, WAGNER A, MATHUS-VLIEGEN E M, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations[J]. Am J Gastroenterol, 2010, 105(6):1258-1264. |
| [15] | ZHANG J, WANG N, ZHENG T, et al. Germline mutational landscape in Chinese patients with advanced breast cancer[J]. Front Oncol, 2022,12:745796. |
/
| 〈 |
|
〉 |
